alexa Live, Attenuated Vaccines In Animal Health: VitamFeros Products And A Few Others
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

16th Euro Global Summit and Expo on Vaccines & Vaccination
June 19-21, 2017 Paris, France

Pascal Breton
VitamFero, France
Keynote: J Vaccines Vaccin
DOI: 10.4172/2157-7560-C1-056
Abstract
Market Overview: The global animal vaccines market was around US$6 billion in 2016 and progressing at a compound annual growth rate of 5-7%. Although the largest markets are Europe and North America, fastest growth is in Asia-Pacific. About 62% is for livestock and 38% for domestic animal with faster growth is in domestic animal vs. livestock segment. The vaccines segment is most lucrative of all veterinary segments, just ahead of “parasitides”. Market Drivers: Increased demand in the companion market is due to increased pet ownership and increased discretionary spending by “empty nesters” and growing income in Asia-Pacific. Increased demand among livestock is driven by increasing demand for meat, a movement to organic farming and prevention, and increasing awareness/incidence of zoonotic illnesses (Avian flu, etc.). Technological Factors: Live, attenuated vaccines based on genetic mutation and engineering is to be the dominant segment due to better targeting/efficiency, long-term immunity and ease of administration. VitamFero Deploys a Novel Parasite-based Vaccine Platform: VitamFero develops proprietary and unique eukaryote (apicomplexan parasites: Toxoplasma gondii or Neospora caninum)-based live, attenuated vaccines. The molecular basis of attenuation results from targeted, total gene deletion that is fully mastered and characterized. Further to being highly effective in preventing ovine toxoplasmosis, bovine neosporosis, cryptosporidiosis, etc., without requiring adjuvant, these innovative prophylactic agents eliminate all risk of return to virulence under environmental forces. Conveniently stored at 4ºC in a freezedried bio-formulation stable for at least 8 months, VitamFero’s genetically-modified parasites exhibit a better benefit/risk ratio than currently-marketed vaccines and immunostimulants, and can also be used as vectors for antigen expression.
Biography

Pascal Breton serves as the Chief Executive Officer of VitamFero SA and was the President of VitamFero SA since January 2009. His interest includes biotechnology, R&D, business development, drug development, pharma/clinical development, drug discovery and formulation and vaccines. He has also worked as the Global Key Account Manager at SGS Life Science Services (Belgium), Director Business Development at IDM Pharma (France and USA), Director R&D at Halisol (France) and Project Leader at UPSA (a French BMS subsidiary). He holds a PhD from University of Orléans (France) in 1989.

Email: [email protected]

image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords